Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug ...

Response rates with encorafenib-cetuximab plus FOLFIRI similar to combo plus modified FOLF ...

Amivantamab combined with FOLFOX or FOLFIRI showed a 51% overall response rate in RAS/BRAF wild-type mCRC patients, with a ...

In the evolving landscape of metastatic colorectal cancer, managing patients with RAS/BRAF wild-type tumors remains a ...

Oral anticoagulant use was associated with a reduced risk for progression of 60% and a reduced risk for death of 76% in ...

EVOKE-02: A phase 2 study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) with or without platinum chemotherapy in first-line metastatic non–small cell lung cancer (NSCLC). Background: KRAS ...

In BREAKWATER, EC plus FOLFIRI achieved a 64.4% response rate and showed a trend toward improved overall survival in patients ...

Personalized Medicine. 2013;10(4):405-412. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with ...

Ketones are produced when the body runs low on glucose supplies and starts to burn fat, something that most of us aim for at the gym. This is not a metabolic pathway that one would associate with the ...

Bringing people together is a nonprofit’s strength, according to a Q&A with Chris Meyer, who was named CEO of the Baton Rouge Area Foundation. Meyer returned to Louisiana “armed with important lessons ...